Aska Pharmaceutical Co Sustainability Profile
Aska Pharmaceutical Co., Ltd., commonly referred to as Aska Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan (JP). Established in 1941, the company has made significant strides in developing innovative healthcare solutions, particularly in the fields of prescription pharmaceuticals and over-the-counter products. With a strong operational presence in Asia and beyond, Aska Pharma focuses on therapeutic areas such as cardiovascular, oncology, and infectious diseases. Their core offerings include unique formulations and advanced drug delivery systems that set them apart in a competitive market. Recognised for their commitment to quality and research, Aska Pharmaceutical has achieved notable milestones, including strategic partnerships and a robust pipeline of new drugs. Their dedication to improving patient outcomes solidifies their position as a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Aska Pharmaceutical Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aska Pharmaceutical Co's score of 27 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aska Pharmaceutical Co's reported carbon emissions
Aska Pharmaceutical Co, headquartered in Japan, reported its carbon emissions for the year 2022, totalling approximately 6,687,000 kg CO2e for Scope 1 and about 4,093,000 kg CO2e for Scope 2. This marks a reduction from 2021, where emissions were approximately 7,209,000 kg CO2e for Scope 1 and around 5,042,000 kg CO2e for Scope 2. In 2020, the company recorded total emissions of about 13,215,000 kg CO2e, with Scope 1 emissions at approximately 7,443,000 kg CO2e and Scope 2 at about 5,771,000 kg CO2e. Despite these reductions, Aska Pharmaceutical Co has not set specific science-based targets (SBTi) or documented reduction initiatives. The company does not disclose any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. Overall, Aska Pharmaceutical Co's commitment to reducing its carbon footprint is evident through its decreasing emissions over the past few years, although further transparency regarding future climate commitments and targets would enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 7,443,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,771,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Aska Pharmaceutical Co's Industry?
How Carbon Intensive is Aska Pharmaceutical Co's Location?
Aska Pharmaceutical Co's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aska Pharmaceutical Co has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
